Effects of ketanserin on transmembrane sodium transport in erythrocytes. 1990

L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
Hypertension Unit, University of Sassari, Italy.

Ketanserin, an antagonist of 5-HT2-serotonergic and alpha 1-adrenergic receptors, has come into use for the therapy of mild to moderate arterial hypertension. Quite recent observations have shown changes in transmembrane sodium (Na) transport after the acute administration of high doses of this drug to normal subjects. It is well known that some of these transport systems have an altered activity in essential hypertension. We evaluated the effects of long-term (3 months) administration of ketanserin (40-80 mg/day) on Na and potassium (K) intracellular concentrations and transmembrane fluxes in red blood cells (RBCs) from 12 essential hypertensive patients. In addition the present study describes the in vitro effects of two different concentrations of the drug (5 x 10(-8) and 5 x 10(-7) M) on erythrocytes in normal subjects. In the first study, both systolic and diastolic blood pressure were significantly lowered by the treatment with ketanserin (from 165/103 to 143/89; p less than 0.001). Na and K intraerythrocyte concentrations fell markedly during ketanserin administration (both p less than 0.001). A marked decrease in Na,K-pump activity (p less than 0.001) and an increase in Na,lithium(Li)-countertransport function (p less than 0.001) were observed. Na outward cotransport, Na leak, and K leak were not modified by the therapy. Direct correlation was found between the fall in mean blood pressure and in Na and K intraerythrocyte concentration (respectively, p less than 0.01 and p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
January 1985, Journal of cardiovascular pharmacology,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
January 1972, Medicina,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
June 1985, Bollettino della Societa italiana di biologia sperimentale,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
January 1974, The Journal of biological chemistry,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
November 1969, The American journal of physiology,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
November 1973, Research in veterinary science,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
August 1985, Clinical science (London, England : 1979),
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
January 1983, Clinical science (London, England : 1979),
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
November 1987, Kidney international,
L A Sechi, and R Tedde, and L Cassisa, and A Marigliano, and F Uneddu, and A Melis, and A Pala
February 1974, Archives of biochemistry and biophysics,
Copied contents to your clipboard!